ロード中...
Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn’s Disease Studies
BACKGROUND AND AIMS: Analyses of Crohn’s Disease [CD] studies of anti-TNF agents, including adalimumab, have reported higher remission rates among patients with shorter disease duration. To further explore the relationship between disease duration and clinical efficacy, we analysed a larger patient...
保存先:
| 出版年: | J Crohns Colitis |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6535500/ https://ncbi.nlm.nih.gov/pubmed/30753371 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ecco-jcc/jjy223 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|